The Oncology Institute Reports Third Quarter 2024 Financial Results

Oncology Institute Inc Stock Price - TOI | ADVFN

The Oncology Institute Reports Third Quarter 2024 Financial Results. CERRITOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ ...

Q3 2024 Oncology Institute Inc Earnings Call Transcript - GuruFocus

Good afternoon and welcome to the Oncology Institute third quarter, 2024 earnings conference call. Today's call is being recorded and we have ...

Checkpoint Therapeutics Reports Third Quarter 2024 Financial ...

R&D Expenses: Research and development expenses for the third quarter of 2024 were $6.4 million, compared to $5.5 million for the third quarter ...

Gilead Sciences Announces Second Quarter 2024 Financial Results

Total second quarter 2024 revenue increased 5% to $7.0 billion, compared to the same period in 2023, primarily due to higher product sales in ...

Gritstone bio Reports First Quarter 2024 Financial Results and ...

General and administrative expenses were $8.5 million for the three months ended March 31, 2024 compared to $6.7 million for the three months ...

Nuvalent Highlights Corporate and Pipeline Achievements ...

... Reports Third Quarter 2024 Financial Results. Nuvalent, Inc ... Oncology (ESMO) Congress 2024. Data presented showed that treatment with ...

The Oncology Institute News | Markets Insider

The Oncology Institute Reports Second Quarter 2024 Financial Results and Updates Full Year 2024 Guidance. GlobeNewswire 96d. Constellation Software Inc. and ...

Predictive Oncology Reports Third Quarter 2024 Financial Results ...

Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update ; Revenue, $, 345,686 ; Cost of sales, 196,919 ...

CG Oncology Reports Third Quarter 2024 Financial Results and ...

Research and Development (R&D) Expenses: R&D expenses for the three months ended September 30, 2024 were $19.6 million compared with $11.7 ...

Ligand Reports Third Quarter 2024 Financial Results and Raises ...

Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 ...

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results ...

The net loss for the third quarter of 2024 was $9.5 million, compared to a net loss of $9.9 million for the third quarter of 2023. The basic and ...

The Oncology Institute, Inc. (TOI) Stock Price, Quote & News

The Oncology Institute Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance ... CERRITOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ...

The Oncology Institute, Inc. (TOI) Stock Price, Quote, News & Analysis

Press Releases · The Oncology Institute Reports Third Quarter 2024 Financial Results · The Oncology Institute Announces Certification to Administer Pluvicto ...

Century Therapeutics Reports Third Quarter 2024 Financial Results ...

Net cash used in operations was $85.9 million for the nine months ended September 30, 2024, compared to net cash used in operations of $62.1 ...

ImmunityBio Reports Third-Quarter 2024 Financial Results

Selling, general and administrative expenses increased $4.1 million to $35.9 million during the three months ended September 30, 2024, as ...

The Oncology Institute Reports Third Quarter 2023 Financial Results ...

The Oncology Institute Reports Third Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance ; Patient services, $, 53,634 ...

AN2 Therapeutics Reports Third Quarter 2024 Financial Results ...

Net loss: Net loss for the third quarter of 2024 was $12.7 million, compared to $16.7 million for the same period during 2023. Cash Position: ...

Checkpoint Therapeutics Reports Third Quarter 2024 Financial ...

Net loss for the third quarter of 2024 included $1.9 million of non-cash stock expenses, compared to $0.9 million for the third quarter of 2023.

Lilly reports Q3 2024 financial results highlighted by strong volume ...

In Q3 2024, worldwide revenue was $11.44 billion, an increase of 20% compared with Q3 2023, driven by a 15% increase in volume and a 6% increase due to higher ...

ALX Oncology Reports Third Quarter 2024 Financial Results and ...

These expenses for the three months ended September 30, 2024, were $26.5 million, compared to $45.8 million for the prior-year period. R&D ...